[Pharmacokinetics of a long-circulating PEGylated Radix Ophiopogonis polysaccharide].

The pharmacokinetics of a long-circulating PEGylated Radix Ophiopogonis polysaccharide (ROP) was investigated in rats following i.v. or s.

Long-circulating delivery of bioactive polysaccharide from radix ophiopogonis by PEGylation.

Background: Radix ophiopogonis polysaccharide (ROP) has been found to be effective against myocardial ischemia. One of main problems with its use is its short in-vivo half-life, which makes the development of an effective delivery system necessary. To achieve better therapeutic effects and patient compliance by prolonging its retention in plasma and increasing its distribution in targets, ROP was PEGylated (PEG, polyethylene glycol) in this study.

Comparison of tissue distribution of a PEGylated Radix Ophiopogonis polysaccharide in mice with normal and ischemic myocardium.

PEGylation was found to be a promising approach to improve the anti-myocardial ischemic activity of Radix Ophiopogonis polysaccharide (ROP) by prolonging its retention in plasma. To fully evaluate the effectiveness and safety of this strategy, the tissue distribution of PEGylated ROP was investigated in this study. A long-circulating and bioactive PEGylated ROP with 1.

Poly(ethylene glycol)-radix Ophiopogonis polysaccharide conjugates: preparation, characterization, pharmacokinetics and in vitro bioactivity.

Radix Ophiopogonis polysaccharide (ROP), a natural graminan-type fructan with Mw of ∼5kDa, had been found to have an excellent anti-myocardial ischemic activity. However, its rapid renal excretion following administration remarkably limits its efficacy and clinical use, which makes necessary the development of an effective delivery system. In this article, the feasibility of PEGylation to solve this problem was examined.